A real-world pharmacovigilance study of romidepsin based on FDA adverse event reporting system database
{{output}}
Background: Romidepsin is a class I-selective histone deacetylase (HDAC) inhibitor indicated for the treatment of adult patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy and for ... ...
